NIDA explores in this video the intriguing similarities between the processes of brain development and computer programming. The analogy helps us understand why toxic environmental factors like dru...
Dr. Nora Volkow, Director of the National Institute of Drug Abuse (NIDA) at the National Institutes of Health, discusses findings from the 44th annual Monitoring the Future (MTF) survey, released ...
Dr. Zheng-Xiong Xi discusses why marijuana sometimes causes aversive effects, and the compounds that show promise for treating cocaine or opioid addictions. Read the accompanying NIDA Notes article...
NIDA grantee Rajita Sinha discusses the importance of considering sex and gender differences while studying the causes and treatment of substance use disorders, including the differences between se...
NIDA grantee Rajita Sinha discusses the importance of considering sex and gender differences while studying the causes and treatment of substance use disorders, including the differences between se...
NIDA grantee Rajita Sinha discusses the importance of considering sex and gender differences while studying the causes and treatment of substance use disorders, including the differences between se...
NIDA grantee Rajita Sinha discusses the importance of considering sex and gender differences while studying the causes and treatment of substance use disorders, including the differences between se...
NIDA grantee Rajita Sinha discusses the importance of considering sex and gender differences while studying the causes and treatment of substance use disorders, including the differences between se...
NIDA grantee Rajita Sinha discusses the importance of considering sex and gender differences while studying the causes and treatment of substance use disorders, including the differences between se...
NIDA grantee Rajita Sinha discusses the importance of considering sex and gender differences while studying the causes and treatment of substance use disorders. In this segment she discusses the ef...
NIDA Director Dr. Nora Volkow discusses the public health impact of the Food and Drug Administration-approved intranasal naloxone and the importance of public/private partnerships.